The clinical analyz of pregnancy terminastions with oksitosin/dinoproston (preeclamptic-nonpreeklamptic) term pregnancies

Abstract

Objective: The aim of our study is to compare the efficacy, safety and complications of pharmacological agents of Oxytocine and Dinoprostone and oxytocine + dinoprostone combination which are frequently used for cervical ripening and for labor induction in women with a gestational age of 37 weeks and over 37 weeks and an indication for termination of pregnancy. Materials and Methods: A total of 173 pregnant women with a gestational age of 37 weeks-and over 37 weeks were included into this study. First group applied oxytocine, Second group applied dinoprostone, Third group applied dinoprostone+ oxytocine. In our study, we also compared the presence of preeclampsia with the patients not having preeclampsia in regard to bishop score changes and the time from placement until delivery. Results: We determined the average time from placement until delivery in the patients included into the study to be 19.2 hour in oxytocine group, 21.4 hour in dinoprostone group and 18.9 hour in oxytocine + dinoprostone group. Among the groups, rates of vaginal deliveries within the first 24 hours were determined to be 43.1% in oxytocine group, 32,3% in dinoprostone group and 42,8% in oxytocine + dinoprostone group. In our study, durations of vaginal deliveries, rates of vaginal and caesarean- section deliveries, bishop score changes, amounts of meconium, the mean 1st minute and 5th minute Apgar scores were similar in each of three groups except a higher rate of hyperstimulation in dinoprostone group. We also determined that the presence of preeclampsia did not affect bishop score changes and the time from placement until delivery. Conclusion: Each of three agents can be used alternatives of each other for cervical ripening and labor induction.

Keywords

• Dinoprostone,Oxytocin,Term Birth,Gestational Age,Pre-Eclampsia,Pregnancy Complications,Time

Term gebeliklerde (preeklamptik-diğer) oksitosin/dinoproston yardımlı gebelik terminasyonlannın klinik analizi

Öz

Amaç: Çalışmamızın amacı 37 hafta ve üstü gebelik terminasyonu endikasyonu verilen olgularda serviksi olgunlaştırma ve doğum eylemi indüksiyonunda sık kullanılan ajanlardan Oksitosin, Dinoproston veoksitosin+dinoproston 'u; etkinlik, güvenirlilik ve komplikasyonlar açısından karşılaştırmaktır. Materyal ve metod: Bu çalışmaya 3 7 veya daha büyük gebelik haftasında bulunan toplam 173 gebe kadın dahil edildi. 1.gruba oksitosin, 2.gruba dinoposton. 3.gruba dinoposton+oksitosin uygulandı. Çalışmamızda ayrıca preeklampsi varlığını, bishop skoru değişiklikleri ve uygulamadan doğuma kadar geçen süre açımndan preeklamptik olmayan hastalarla karşılaştırdık. Bulgular: Çalışmaya aldığımız hastalarda uygulamadan doğuma kadar geçen süreyi, ortalama olarak oksitosin grubunda 19.2 saat, dinoproston grubunda 21.4 saat, oksitosin+ dinoproston grubunda 18.9 saat olarak bulduk. Gruplar arasında ilk 24 saattteki vajinal doğum oranlarını oksitosin grubunda %43,1, dinoproston grubunda %32,3, oksitosin^dinoproston grubunda ise %42,8 olarak tespit ettik. Çalışmamızda dinoproston grubunda yüksek hiperstimülasyon oranı dışında her üç grupta vajinal doğum süresi, vajinal ve sezeryan doğum oranları, bishop skorundaki değişimler, mekonyum oranları, 1. dakika ve 5. dakika apgar skor ortalamaları benzer bulunmuştur. Preeklampsi varlığının da bishop skoru değişiklikleri ve uygulamadan doğuma kadar geçen süreyi etkilemediğini tespit ettik. Sonuç: Servikal olgunlaşma ve doğum indüksiyonu için her üç ajan birbirinin alternatifi olarak kullanılabilir.

Anahtar Kelimeler

• Dinoproston,Oksitosin,Zamanında doğum,Gebelik yaşı,Preeklampsi,Gebelik komplikasyonları,Zaman

Kaynakça

1. 1) Beebe LA, Raybum WF, Beaty CM, Eberly KL, Stanley JR, Raybuni LA. Indications for labor induction. Differences between university and community hospitals. J Reprod Med 2000; 45:463- 75
2. 2) Bishop EH. Pelvic scoring for elective induction. Obstet Gynecol 1964;24:266-8
3. 3) Ulmsten U, Wingerup L, Ekman G. Local application of prostaglandin E2 for cervical ripening or induction of term labour. Clin Obstet Gynecol 1983:26:95-105
4. 4) Casey C, Kehoe J, Mylotte M. Vaginal prostaglandins for the ripe cervix. Int J Gynaecol Obstet 1994;1:21-26
5. 5) Hofmeyr GJ, Z Alfirevic, J Kavanagh, J Thomas, P Brocklehurst, JP Neils on: Methods for cervical ripening and labor induction in late pregnancy: generic protocol. Cochrane Database Syst Rev 2000 6) Kelly A J, Z Alfirevic, GJ Hofmeyr, J Kavanagh, JP Neilson, J Thomas: Induction of labor in specific clinical situations: generic protocol. Cochrane Database Syst Rev 2001 7) Cabrol D, Dobbis C, Cronje H, Gonnet M, Guillot M, Maria B, Moodley J, Oury JF: Induction of labor with mifepristone in intrauterine fetal death. Am.J.Obs.Gyn. , 1990.163, 540-542 8) Lin A, Kopfermine M, Dooley SL: Arandomized trial of extraamniotic saline infusion versus lamineria for cervical ripening. Obs. Gyn. ,1995, 86; 545-549
6. 9) Herabotya Y, Prasersawat PO,: Induction of labor using intraservical prostaglandin gel: The outcome. J.Med.Assoc. Thai. ,1991. ,74;491-497 10) FrydmanR, Lelaidier C, Mleux BSC, Fernandez H, Vial M, Bourget P: Labor induction in women at term with mifepristone (RU 486): a double- blind,randomized, placebo-controlled study. Obstet. Gynecol. 1992, 80; 972-975 11) Wing DA.; , Misoprostol vaginal insert compared with dinoprostone vaginal insert: a randomized controlled trial, 2008 0ct;112(4):801- 12 12) Kho EM., Sadler L, McCowan L ., Induction of labour: a comparison between controlled-release dinoprostone vaginal pessary (Cervidil) and dinoprostone intravaginal gel (Prostin E2)., 2008 Oct;48(5):473-7
7. 13) Fekih M. ,Ben Zina N ,Jnifen A ,Nouri S ,Ben Regaya L ,Memmi A ,Bouguizene S, Chaieb A ,Bibi M ,Sboui H ,Khairi H, Comparing two Prepidil gel regimens for cervical ripening before induction of labor at term: a randomized trial, 2009 Jun;38(4):335-40. Epub 2009 May 21 14) Anna Maria Marconi a, Patrizia Bozzetti a, Alberto Morabito b, Giorgio Pardi a, Comparing two dinoprostone agents for cervical ripening and induction of labor: A randomized trial, European Journal of Obstetrics & Gynecology and Reproductive Biology 138 (2008) 135-140 15) BhushanK.Sennik , M.D., F.R.C.S.C.,F.A. C.O.G.; outpatient use of a sustained -release PGF2 vaginal insert -A Retrospektive study; Reprinted from today's therapeutic trends ,2001,19(2):77-84 16) Mc Namara H, Koufogianis A, Benjamin A. Safety and effectiveness of Cervidil for cervical ripening. Canadian phase IV open label study. 55th annual meeting of Society of Obstetrics and Gynecologists of Canada (SGOC), 1999, June 25- 29 Ottowa, Ontaroi
8. 17) Crane JM, Young DC, Butt KD, Bennett KA, Hutchens D. Excessive uterine activity accompanying induced labor. Obstet Gynecol. 2001 Jun;97(6):926-31 18) H. Guler şahin, Hüseyin Avni sahin, and Mustafa KOCER; induction of labor in toxemia with misoprostol; Acta obstet Gynecol Scand;2002, 81:252-257 19) H.G.Shin,R.Surucu, M. Guvercinci; A Study of intravaginal misoprostol for induction of labor in toxemia og pregnancy; international journal of Gynecelogy & obstetrics 75(2001) 3-9 20) Induction of labor with intravaginal misoprostol in hypertensive pregnency. Sebaht gürel, Hulusi gürel. Perinatoloji dergisi 1997-cilt 5-sayı: 1-2/mart- haziran. 4-7